COMPANY OVERVIEW

None

---

LOCATION

---

THERAPEUTIC AREAS

---

WEBSITE

None

---

CAREER WEBSITE

None

---

SOCIAL MEDIA

---

INVESTORS

---

PRESS RELEASES

Sep 26, 2023

Recent Nature publications highlight the groundbreaking performance of RareCyte's Orion Spatial Biology platform

Nov 14, 2022

RareCyte selected for the Wellcome Leap In Utero program; will utilize its rare cell liquid biopsy platform to perform breakthrough research to decrease stillbirth rates worldwide

Jan 6, 2022

RareCyte Inc. reports significant 2021 growth of Precision Biology™ Services business and customer uptake of Orion™ Spatial Biology instruments and reagents

Sep 9, 2021

RareCyte Secures $24M Financing to Advance the Orion™ Spatial Biology Platform and Expand Global Commercial Channels

Aug 26, 2020

RareCyte announces first commercially available ARv7/Synaptophysin CTC assay for blood-based characterization of treatment resistant prostate cancer

For More Press Releases

---